Physician profile
Kristina E Bowen
NPI 1922086784
$41,661.82
in general payments reported to CMS, 2019-2025
21 companies · $735 in 2025
The $735 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $15K · 2021: $8,472 · 2022: $1,788 · 2023: $2,054 · 2024: $568 · 2025: $735.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,393 · Food and Beverage: $614 · Grant: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,392.50 |
| Food and Beverage | $614.23 |
| Grant | $350.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $11,853.33 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $10,849.85 | 2019-2024 | Enhertu, Lynparza |
| Daiichi Sankyo INC. | $9,457.14 | 2019-2025 | Vanflyta, Datroway |
| Seagen INC. | $2,870.00 | 2020 | |
| Gilead Sciences, INC. | $2,100.02 | 2021-2025 | Trodelvy |
| Athenex Pharmaceutical Division, LLC | $2,000.00 | 2021 | |
| Novartis Pharmaceuticals Corporation | $1,783.16 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $153.04 | 2021 | |
| Janssen Biotech, INC. | $87.22 | 2020-2024 | Darzalex, Talvey |
| Exelixis INC. | $82.48 | 2019-2022 | |
| Puma Biotechnology, INC. | $81.18 | 2022-2025 | |
| Abbvie INC. | $67.77 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $51.84 | 2019-2025 | Keytruda |
| Genzyme Corporation | $39.39 | 2023 | |
| Lilly USA, LLC | $35.47 | 2024 | Verzenio, Jaypirca |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stemline Therapeutics INC. | $33.14 | 2025 | Orserdu |
| Celgene Corporation | $27.60 | 2025 | Reblozyl |
| Tempus Ai, INC | $27.12 | 2025 | Xt Cdx |
| Glaxosmithkline, LLC. | $23.49 | 2024 | Jemperli, Zejula |
| Sobi, INC | $20.05 | 2025 | |
| Incyte Corporation | $18.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristina Bowen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.